Cyclized Chimeric Peptides for HER-2 Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for breast cancer, such as surgery, chemotherapy, and radiation, often have significant side effects, and immunotherapeutic approaches targeting the HER-2 protein are uncertain in generating effective immune responses due to its nature as a non-mutated 'self antigen.
Innovation Solution
Development of HER-2 B epitopes and chimeric peptides that mimic the binding sites of trastuzumab and pertuzumab, which are cyclized to enhance humoral response and immune recognition, allowing for the stimulation of an immune response against HER-2 overexpressing cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (surgery, chemotherapy, radiation) are used to treat breast cancer, then tumor cells can be eliminated, but significant side effects occur including immune system interference and toxicity to normal cells
Solution Approach 1:
The invention segments the immune response into two distinct components: B-cell epitopes for antibody production and T-cell helper epitopes for cellular immunity. This segmentation allows targeted stimulation of specific immune mechanisms while sparing normal cells from the broad toxicity of conventional chemotherapy and radiation.
Solution Approach 2:
The chimeric peptide acts as an intermediary that bridges the gap between the HER-2 antigen and the immune system. By incorporating both B-cell and T-cell epitopes, it mediates a coordinated immune response that specifically targets HER-2 overexpressing cells without directly damaging normal cells like conventional treatments do.
2Object-affected harmful factors
If immunotherapeutic approaches targeting HER-2 are used, then a more selective treatment can be achieved, but effective immune responses are uncertain because HER-2 is a non-mutated self antigen
Solution Approach 1:
The invention merges B-cell epitope and T-cell helper epitope into a single chimeric peptide structure. This combination is crucial because T-cell help is necessary to overcome tolerance to self-antigens like HER-2. The T-cell epitope provides the necessary immune activation signals that enable B-cells to produce effective antibodies against the HER-2 B-cell epitope, thereby generating reliable immune responses despite HER-2 being a self-antigen.
Solution Approach 2:
The invention changes the immunological parameters by introducing T-cell helper epitopes that alter the immune system's recognition and response to the HER-2 antigen. This parameter change transforms the immune response from tolerant (due to self-antigen nature) to active and effective, enabling reliable antibody production against HER-2.
3Device complexity
If linear HER-2 peptides are used for immunization, then the structure is simple, but the humoral response is insufficient compared to cyclized peptides
Solution Approach 1:
The invention applies cyclization to the peptide structure, transforming it from a linear chain to a cyclic (ring) structure. This curvature brings the N- and C-termini together, creating a more compact three-dimensional conformation that better mimics the native HER-2 protein structure. This structural change enhances epitope presentation to B-cell receptors, thereby improving antibody production and humoral response.
Data Source
AI summary
Compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include epitopes of the HER-2 proteins.